Eli Lilly and (LLY) Revenue — Quarter Ended Dec 31, 2025
Revenue for the quarter increased compared to both the prior quarter and the same quarter last year, extending a trend of sequential growth. The company continued to benefit from strong demand for its medicines.
Key takeaway
Quarter ended Dec 31, 2025 · FY2025 Q4
Revenue for the quarter increased compared to both the prior quarter and the same quarter last year, extending a trend of sequential growth. The company continued to benefit from strong demand for its medicines.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$19.3B
Revenue reported for this quarter.
Quarter-over-quarter
+9.6%
Change from the immediately preceding quarter.
Year-over-year
+42.6%
Change from the comparable year-ago quarter.
Trailing four quarters
$65.2B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Mar 31, 2025 | $12.7B | +45.2% |
| Jun 30, 2025 | $15.6B | +37.6% |
| Sep 30, 2025 | $17.6B | +53.9% |
| Dec 31, 2025 | $19.3B | +42.6% |
Revenue performance
The reported revenue rose from the immediately preceding quarter and showed a substantial improvement relative to the same period one year earlier. This marks the highest quarterly revenue within the available trend.
Quarterly comparison
Sequentially, revenue grew at a healthy pace, albeit slower than the prior quarter's increase. On a year-over-year basis, the gain was notably stronger, reflecting continued momentum.
What to watch
Capital expenditures have increased meaningfully for manufacturing expansion, and future cash commitments under supply agreements could be sizable.